药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
3,7,11,15-tetramethyl-hexadecan-1-ol
Tregalizumab
The risk or severity of adverse effects can be increased when Tregalizumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Racotumomab
The risk or severity of adverse effects can be increased when Racotumomab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Namilumab
The risk or severity of adverse effects can be increased when Namilumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Rovalpituzumab Tesirine
The risk or severity of adverse effects can be increased when Rovalpituzumab Tesirine is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Robatumumab
The risk or severity of adverse effects can be increased when Robatumumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Milatuzumab
The risk or severity of adverse effects can be increased when Milatuzumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Bimekizumab
The risk or severity of adverse effects can be increased when Bimekizumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Sacituzumab govitecan
The risk or severity of adverse effects can be increased when Sacituzumab govitecan is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Ozanezumab
The risk or severity of adverse effects can be increased when Ozanezumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Clazakizumab
The risk or severity of adverse effects can be increased when Clazakizumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Amatuximab
The risk or severity of adverse effects can be increased when Amatuximab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Rontalizumab
The risk or severity of adverse effects can be increased when Rontalizumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Depatuxizumab
The risk or severity of adverse effects can be increased when Depatuxizumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Concizumab
The risk or severity of adverse effects can be increased when Concizumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Crotedumab
The risk or severity of adverse effects can be increased when Crotedumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Naptumomab Estafenatox
The risk or severity of adverse effects can be increased when Naptumomab Estafenatox is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Ecromeximab
The risk or severity of adverse effects can be increased when Ecromeximab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Abituzumab
The risk or severity of adverse effects can be increased when Abituzumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Sifalimumab
The risk or severity of adverse effects can be increased when Sifalimumab is combined with Belantamab mafodotin.
3,7,11,15-tetramethyl-hexadecan-1-ol
Demcizumab
The risk or severity of adverse effects can be increased when Demcizumab is combined with Belantamab mafodotin.